



June 30, 2017

Dear Colleague:

eviCore healthcare (eviCore) is pleased to announce its expanded relationship with Horizon Blue Cross Blue Shield of New Jersey. It was previously communicated that beginning July 3, 2017, Horizon BCBSNJ would implement a new specialty utilization management program in collaboration with eviCore for certain molecular and genomic diagnostic laboratory testing services. **The program start date is effective August 1, 2017.** Through this new program, which will be known as Horizon BCBSNJ's Molecular and Genomic Testing Program, eviCore will conduct pre- and post-service Medical Necessity Determination (MND) reviews of certain molecular and genomic diagnostic testing services that are rendered in the following settings¹:

- Physician's office
- Clinical laboratory

This program applies only to laboratory services to be provided to members enrolled in Horizon BCBSNJ fully-insured products, as well as Administrative Services Only (ASO) accounts that have elected to participate in the Molecular and Genomic Testing Program administered by eviCore. Note: Members enrolled in Medicare Advantage (MA) plans are excluded from this program.

Effective **August 1, 2017**, eviCore will conduct MND reviews of certain molecular and genomic tests within the following categories:

- Hereditary cancer screening
- Carrier screening tests
- Tumor marker/molecular profiling
- Hereditary cardiac disorders
- Cardiovascular disease and thrombosis risk variant testing
- Pharmacogenomic testing
- Neurologic disorders
- Mitochondrial disease testing
- Intellectual neurologic disorders

A listing of the procedure codes subject to MND review as part of this program can be accessed online at **HorizonBlue.com/molecularnotice**.

Claims for molecular and genomic testing services provided on and after **August 1, 2017**, for which no pre-service MND is obtained, will be delayed or denied while information for eviCore to conduct a post-service MND review is requested and reviewed. Claims for molecular and genomic testing deemed not medically necessary through post-service review will not be considered for reimbursement.

As part of this program, claims for all molecular and genomic testing services within the scope of this new program rendered on and after **August 1, 2017** will be processed and reimbursed in a manner that is consistent with eviCore's guidelines in regard to molecular and genomic testing service frequency rules and service maximums. Visit **www.evicore.com/healthplan/Horizon_Lab** to review these guidelines.

¹MND requirements will not apply to molecular and genomic diagnostic testing services rendered to patients in a hospital Emergency Room, hospital outpatient or inpatient setting, or an Ambulatory Surgery Center (ASC).

To request an MND, log onto **eviCore.com** to submit your request on our authorization page. You may also call **1-844-224-0493** between 7 a.m. and 7 p.m., Eastern Time.

For urgent requests: If services are required in less than 24 hours due to medically urgent conditions, please call our toll-free number for expedited MND reviews. Be sure to tell our representative the MND is for medically urgent care.

Have questions about requesting an MND? Attend our online orientation! The orientation schedule and program training resources are available at **www.evicore.com/healthplan/Horizon_Lab**. Please call our Customer Service department at **1-844-224-0493** if you have any questions or need more information.

Sincerely,

Gregg P. Allen, M.D.
Chief Medical Officer
eviCore healthcare